Fostamatinib
Tavalisse (fostamatinib) is an oral prescription drug manufactured by Rigel Pharmaceuticals, Inc., available as 100mg and 150mg tablets. It is used to treat low platelet counts in adults with chronic immune thrombocytopenia (ITP) who haven't responded well to other treatments. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Tavalisse (fostamatinib) is an oral prescription drug manufactured by Rigel Pharmaceuticals, Inc., available as 100mg and 150mg tablets. It is used to treat low platelet counts in adults with chronic immune thrombocytopenia (ITP) who haven't responded well to other treatments. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Fostamatinib",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Fostamatinib — ANDA 209299 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209299"
}
]
|
| identifier | ANDA209299 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-information",
"drug-manufacturers",
"medications",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Fostamatinib |
